LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports.

After hours: November 29 at 3:31 PM EST Loading Chart for LMAT ...

Only one study evaluating the efficacy and safety of tinzaparin for the treatment of DVT has been published. In a multicenter, randomized, double-blind trial by the American- Canadian Thrombosis ...